Da Vinci Spa Kft.

Pecs 17 trials 7 recruiting

17 Registered trials

7 Currently recruiting

Organisation

Da Vinci Spa Kft.

Location

Pecs, Hungary

Identifier

ORG-100046474

Address

Malics Otto Utca 1, 7635, Hungary

Departments

-
Cardiology Department
DaVinci Magánklinika, Kardiológia
Kardiologia
N/A
NA
Pulmonológia

Clinical trials at this site (17)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Phase 2 Study of the Effects and Safety of PF-07328948 in Adults with Heart Failure (BRANCH-HF) Recruiting

2024-518438-94-00 Heart failure 4 2025-10-24
FORTIFY – Focused Orticumab Research for Treating inflammation in Coronary Arteries Recruiting

2025-520464-17-00 Atherosclerotic Cardiovascular disease 4 2025-10-21
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-to-Severe Asthma Recruiting

2024-517866-40-00 Moderate-to-severe Asthma 4 2025-09-29
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended

2023-509301-80-00 Severe hypertriglyceridemia (SHTG) 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-29
A study to investigate the effect on lung function of an approved COPD treatment (BGF, with HFA propellant) compared to BGF formulated with… Ended

2023-506565-57-00 Moderate to Severe Chronic Obstructive Pulmonary Diseas 5 2024-06-21
A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure… Ended

2023-507640-36-00 Resistant hypertension (rHTN) defined as blood pressure 5 2024-04-29
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
"A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended

2023-505787-11-00 Severe and inadequately controlled asthma 5 2021-04-29
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12